- <![CDATA[EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy]]><![CDATA[In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung…onclive · 2mo ago↗ source
- <![CDATA[Sequencing ADCs in Endometrial Cancer]]><![CDATA[Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.]]>onclive · 2mo ago↗ source
- <![CDATA[Second Clinical Scenario - Progressive Disease Despite Hematocrit Control]]><![CDATA[Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.]]>